High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report
© Mackey and Anbar; licensee BioMed Central Ltd. 2004
Received: 26 May 2004
Accepted: 13 September 2004
Published: 13 September 2004
Lung disease in patients with cystic fibrosis is thought to develop as a result of airway inflammation, infection, and obstruction. Pulmonary therapies for cystic fibrosis that reduce airway inflammation include corticosteroids, rhDNase, antibiotics, and high-dose ibuprofen. Despite evidence that high-dose ibuprofen slows the progression of lung disease in patients with cystic fibrosis, many clinicians have chosen not to use this therapy because of concerns regarding potential side effects, especially gastrointestinal bleeding. However, studies have shown a low incidence of gastrointestinal ulceration and bleeding in patients with cystic fibrosis who have been treated with high-dose ibuprofen.
The described case illustrates a life-threatening upper gastrointestinal bleed that may have resulted from high-dose ibuprofen therapy in a patient with CF who had undergone a pneumonectomy. Mediastinal shift post-pneumonectomy distorted the patient's esophageal anatomy and may have caused decreased esophageal motility, which led to prolonged contact of the ibuprofen with the esophagus. The concentrated effect of the ibuprofen, as well as its systemic effects, probably contributed to the occurrence of the bleed in this patient.
This report demonstrates that gastrointestinal tract anatomical abnormalities or dysmotility may be contraindications for therapy with high-dose ibuprofen in patients with cystic fibrosis.
Keywordscystic fibrosis esophageal ulceration gastrointestinal bleed ibuprofen pneumonectomy
Airway inflammation is thought to cause much of the lung damage in patients with cystic fibrosis (CF) [1, 2]. Such inflammation has been found in infants with CF, even in the absence of bacterial infections or symptomatic lung disease .
Recent therapies for CF lung disease have been shown to preserve lung function by decreasing airway exposure to inflammation. For example, airway clearance, antibiotics (inhaled tobramycin and oral azithromycin), rhDNase, and oral corticosteroids have been used to help decrease airway inflammation [4–6]. High-dose ibuprofen therapy also has been shown to be effective in decreasing inflammation, probably by decreasing polymorphonuclear cell influx into the lungs . We present a patient with CF who developed a rare complication of high-dose ibuprofen therapy related to his pneumonectomy.
The patient was a teenager with CF who suffered for several years from right lower lobe consolidation, as a result of recurrent Pseudomonas aeruginosa pneumonia. The consolidation was unresponsive to intensive therapy including intravenous (IV) antibiotics, chest physiotherapy, systemic steroids, and rhDNase. The patient developed recurrent severe pulmonary exacerbations necessitating IV antibiotic therapy 4 times per year between the ages of 14 and 15 years. A computerized tomography scan of the chest when the patient was 15-years-old revealed complete collapse of his right lung. A ventilation/perfusion scan revealed only 8% of his ventilation and perfusion in his right chest, while the remaining 92% was in his left chest. In addition, the left lung had begun to herniate into his right chest. It was felt that the right lung was a recurrent source of infection, which was causing serious morbidity. Therefore, the patient underwent a total right pneumonectomy that he tolerated well.
Approximately one year later, in preparation for initiating high-dose ibuprofen therapy, the patient's stool was checked for occult blood. He was found to have occasional guaiac positive stools. An upper gastrointestinal endoscopy revealed chronic esophagitis, esophageal ulcerations, and Barrett's esophagus thought to be attributable to gastroesophageal reflux. A 24-hour pH probe revealed significant gastroesophageal reflux despite anti-reflux therapy. Therefore, a fundoplication was performed in order to prevent further esophageal damage. Subsequently, it was believed that his esophageal ulcerations resolved as multiple stools were documented to be guaiac negative.
Following this episode the patient's ibuprofen was discontinued, and his oral medications (e.g., antibiotics and vitamins) were switched to liquid form, whenever possible. His pancreatic enzymes were administered after removing the enzyme microspheres from their capsule and mixing them in applesauce.
Reported complications of pneumonectomy include mediastinal shift with herniation of the remaining lung, cardiac herniation, cardiac arrhythmias, bronchopleural fistula, esophageal motility disorders, and development of scoliosis [9–11]. It is thought that pediatric patients have more mediastinal shift following pneumonectomy than adults because of increased elasticity and compliance of the lung and mediastinum that allow for more severe anatomical derangements . A study of 17 post-pneumonectomy pediatric patients revealed that all of the patients had marked herniation of the remaining lung with a mediastinal shift to the opposite side as evident on chest radiographs or computerized tomography scans . One patient with a right pneumonectomy displayed excessive shift of the esophagus as well, but did not have any associated dysphagia or reflux . In another study, esophageal motility was measured in 13 patients before and after pneumonectomy . Patients post-pneumonectomy were shown to have esophageal dysmotility even without reporting dysphagia . The dysmotility was thought to be attributable to the mediastinal shift . Thus, for the patient in the present report, it is likely that the deleterious effects of gastroesophageal reflux may have been increased because of esophageal dysmotility after pneumonectomy.
In our patient, esophageal dysmotility along with the distortion of esophageal anatomy probably combined to slow the esophageal transit time of the ingested ibuprofen, which may have led to development of ulcerations as a result of prolonged concentrated contact within the esophagus. Also, the ibuprofen could have contributed to the development of ulcerations by inhibiting cyclooxygenase systemically, which decreased prostaglandin E production . In turn, less prostaglandin E was available to promote bicarbonate and mucus secretion, which are protective of the gastrointestinal mucosa .
Delayed esophageal transit may have occurred with the patient's other oral medications prior initiation of ibuprofen. For example, his pancreatic enzymes likely were retained in the same esophageal segment, which placed him at risk of developing esophageal damage akin to the development of fibrosing colonopathy and strictures described in patients with CF who received high-dose pancreatic enzymes . The enzymes may have remained inactive because the environment was not alkaline enough for their activation , which may be the reason that the patient did not demonstrate esophageal strictures.
According to the 2002 CF Foundation registry, only 3.8% of patients in North America with CF were treated with high-dose ibuprofen . In 1999, a survey of 67 CF center physicians revealed that safety issues were a major reason that they did not prescribe this therapy . Gastrointestinal bleeding, a known adverse effect of non-steroidal anti-inflammatory agents, was the safety issue of most concern to these physicians . Other known side-effects of high-dose ibuprofen include renal failure (often transient), and epistaxis [3, 17].
The initial randomized, double-blind, placebo control study of high-dose ibuprofen in CF did not demonstrate serious side effects during 4 years of therapy with ibuprofen sufficient to achieve peak plasma concentrations of 50–100 mcg/L . Seven of 85 study patients developed abdominal pain, while only 2 of these 7 were on ibuprofen. One patient in the placebo group developed esophagitis. Of note, abdominal pain, which is very common in patients with CF, actually improved in many patients. In another randomized, double-blind, placebo controlled study, involving 19 children with cystic fibrosis; 13 children received sufficient ibuprofen for 26 months to maximum concentrations 48 +/- 17 mcg/ml, but no adverse effects could be attributed to the ibuprofen .
The incidence of gastrointestinal disease in patients reported to the CF Foundation registry from 1996–2000, was compared between patients who were and were not taking ibuprofen . Peptic ulcer disease was reported in 0.32% of 1,186 CF patients taking high-dose ibuprofen, as compared to an incidence of 0.22% in 18,587 patients not taking ibuprofen. Gastrointestinal bleeding was reported in 0.49% of patients taking ibuprofen, as compared to 0.23% of the others (p = .0004). In the first year after initiation of high-dose ibuprofen therapy for 91 patients at the Texas Children's Hospital CF Center, one patient developed upper gastrointestinal bleeding, and one developed gastritis . In a published case report, a 12-year-old patient with CF on high-dose ibuprofen developed emesis and feeding intolerance . She was found to have pyloric channel stricture as a result of healing antral and pyloric ulcers, which may have been caused by ibuprofen.
The risk of developing gastrointestinal side-effects from high-dose ibuprofen therapy is low for patients with CF. However, ibuprofen may be contraindicated for those who are at increased risk because of gastroesophageal reflux, history of gastrointestinal ulcerations, or abnormal gastrointestinal motility or anatomy.
Written consent was obtained from the patient's mother for publication of this report.
- Oermann CM: Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: Past, present and future. Current Opinion in Investigational Drugs. 2001, 2: 900-906.PubMedGoogle Scholar
- Chmiel JF, Berger M, Konstan MW: The role of inflammation in the pathophysiology of CF lung disease. Clinical Reviews in Allergy and Immunology. 2002, 23: 5-27. 10.1385/CRIAI:23:1:005.View ArticlePubMedGoogle Scholar
- Kennedy MJ: Inflammation and cystic fibrosis pulmonary disease. Pharmacotherapy. 2001, 21: 593-603. 10.1592/phco.21.6.593.34546.View ArticlePubMedGoogle Scholar
- Nguyen T, Louie SG, Beringer PM, Gill MA: Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Current Opinion in Pulmonary Medicine. 2002, 8: 521-528. 10.1097/00063198-200211000-00007.View ArticlePubMedGoogle Scholar
- Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2003, 167: 841-849. 10.1164/rccm.200208-855OC.View ArticlePubMedGoogle Scholar
- Equi A, Balfour-Lynn IM, Bush A, Rosenthal M: Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002, 360: 978-984. 10.1016/S0140-6736(02)11081-6.View ArticlePubMedGoogle Scholar
- Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hillard KA, Hillard JB, Davis PB, Hoppel CL: Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. The Journal of Pharmacology and Experimental Therapeutics. 2003, 306: 1086-1091. 10.1124/jpet.103.052449.View ArticlePubMedGoogle Scholar
- Konstan MW, Byard PJ, Hoppel CH, Davis PB: Effect of high-dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine. 1995, 332: 848-853. 10.1056/NEJM199503303321303.View ArticlePubMedGoogle Scholar
- Kopec SE, Irwin RS, Umali-Torres CB, Balikian JP, Conlan AA: The postpneumonectomy state. Chest. 1998, 114: 1158-1184.View ArticlePubMedGoogle Scholar
- Rasch DK, Grover FL, Schnapf BM, Clarke E, Pollard TG: Right pneumonectomy syndrome in infancy treated with an expandable prosthesis. The Annals of Thoracic Surgery. 1990, 50: 127-129.View ArticlePubMedGoogle Scholar
- Eren S, Eren MN, Balci AE: Pneumonectomy in children for destroyed lung and the long-term consequences. The Journal of Thoracic and Cardiovascular Surgery. 2003, 126: 574-581. 10.1016/S0022-5223(03)00586-5.View ArticlePubMedGoogle Scholar
- Cryer B: Mucosal defense and repair: Role of prostaglandins in the stomach and duodenum. Gastroenterology Clinics of North America. 2001, 30: 877-894.View ArticlePubMedGoogle Scholar
- Reichard KW, Vincour CD, Franco M, Crisci KL, Flick JA, Billmire DF, Schidlow DV, Weintraub WH: Fibrosing colonopathy in children with cystic fibrosis. Journal of Pediatric Surgery. 1997, 32: 237-242. 10.1016/S0022-3468(97)90186-X.View ArticlePubMedGoogle Scholar
- Schibli S, Durie PR, Tullis ED: Proper usage of pancreatic enzymes. Current Opinion in Pulmonary Medicine. 2002, 8: 542-546. 10.1097/00063198-200211000-00010.View ArticlePubMedGoogle Scholar
- Cystic Fibrosis Foundation Patient Registry: Annual Data Report to the Center Directors. Bethesda, Maryland. 2002Google Scholar
- Oermann CM, Sockrider MM, Konstan MW: The use of anti-inflammatory medications in cystic fibrosis. Chest. 1999, 115: 1053-1058. 10.1378/chest.115.4.1053.View ArticlePubMedGoogle Scholar
- Kovesi TA, Swartz R, MacDonald N: Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. New England Journal of Medicine. 1998, 338: 65-66. 10.1056/NEJM199801013380115.View ArticlePubMedGoogle Scholar
- Konstan MW, Hoppel CL, Chai B, Davis PB: Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics. 1991, 118: 956-964.View ArticlePubMedGoogle Scholar
- Konstan MW, Schluchter MD, Storfer-Isser A, Davis PB: Use of ibuprofen for the treatment of airway inflammation in CF: an update. Pediatric Pulmonology. 2002, 34 (suppl 24): 164-165.Google Scholar
- Oermann CM, Sockrider MM, Murry DJ: One year's experience with high-dose ibuprofen therapy in CF [abstract]. Pediatric Pulmonology. 1996, 22 (suppl 13): 280-281.Google Scholar
- Bell EA, Grothe R, Zivkovich V, Foote JM, Wellendorf J: Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. The Annals of Pharmacotherapy. 1999, 33: 693-696. 10.1345/aph.18187.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2431/4/19/prepub
This article is published under license to BioMed Central Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.